The efficacy of drug-coated balloons (DCB) for in-stent restenosis (ISR) in hemodialysis (HD) patients remains unclear.
T he number of patients receiving hemodialysis (HD) is increasing, and the treatment of HD patients is an important challenge in Japan. Coronary artery disease (CAD) is a major concern in patients on HD, and about half of HD patients die from cardiovascular events. 1) Treatment of CAD in HD patients is still uncertain and controversial, because outcomes are much worse after stent implantation in HD patients than in non-HD patients. 2) The benefit of drug-eluting stents (DES) over bare-metal stents (BMS) in these patients remains unclear, although the benefit in non-HD patients is well established. 3) In-stent restenosis (ISR) is also a critical factor for worse outcomes in HD patients. Furthermore, HD patients who have ISR may require PCI several times to treat recurrent ISR, because the standard treatment of ISR in HD patients is not established. A drug-coated balloon (DCB) has been developed and used to treat ISR. Some pivotal studies showed that DCB to treat ISR was noninferior to DES and was superior to ordinary balloon an-gioplasty in non-HD patients. 4, 5) Therefore, it is necessary to examine whether the presence of HD influences prognosis after DCB for ISR. However, because patients with severe renal insufficiency (defined as a glomerular filtration rate !30 mL/minute) were excluded from previous studies, 4, 5) little is known about the efficacy of DCB in HD patients. The objective of the present study was to investigate the efficacy of DCB for ISR in HD patients. An additional objective was to determine whether recurrent ISR and major cardiac adverse events (MACE) occur more frequently in HD patients than in non-HD patients after DCB.
Methods

Study design and population:
The study population consisted of 159 consecutive patients who underwent angioplasty with a paclitaxel-coated balloon (SeQuent Please, B Braun Melsungen) for ISR between February 2014 and June 2017 at the University of Tokyo Hospital. We excluded 6 patients because of the lack of follow-up after discharge (the follow-up rate was 96.2%). The remaining 153 patients were classified into an HD group or a non-HD group (Figure 1 ). HD patients were defined as those who had HD prior to the catheter intervention for ISR. We performed this retrospective study according to the ethical guidelines of our institution.
Hypertension was defined as a systolic blood pressure !140 mmHg, diastolic blood pressure !90 mmHg, or the use of antihypertensive medications. Dyslipidemia was defined as a serum total cholesterol concentration ! 220 mg/dL or the use of antidyslipidemic medications. Diabetes mellitus was defined as a fasting blood glucose concentration !126 mg/dL, hemoglobin A1c (National Glycohemoglobin Standardization Program) ! 6.5%, or the use of antidiabetic medications. PCI procedures and angiographic characteristics: Lesions requiring DCB were characterized according to the modified ACC/AHA guidelines. 6, 7) The severity of calcification of the target lesion based on coronary angiography was semiquantitatively scored, according to the scoring system described by Tsuchihashi, et al. 8) as follows: score 3 for calcification with the same density as bone; score 2 for clear calcification not as dense as healthy bone; and score 1 for fair calcification. ISR was defined as the angiographic detection of a recurrent stenosis with a diameter > 50% in the stented segment or in adjacent segments within 5 mm of the stent edge. Intracoronary isosorbide dinitrate was administered before angiographic assessment. ISR was diagnosed by more than two interventional cardiologists in our facility. Conventional balloon angioplasty was performed to gain access to the lumen of the target vessel before DCB inflation in all procedures. Whether additional procedures such as rotational atherectomy were performed was left to the discretion of the operator. Balloon size and pressure were selected by the op-erator under the guidance of intravascular ultrasound. The DCB size was determined by the previous stent size in the target lesion. Procedure success was defined as residual stenosis < 50% on coronary angiography and adequate DCB inflation for the target lesion. All patients received intravenous heparin (100 IU/kg) during the procedure, and the activated coagulation time was maintained at > 300 seconds. All patients received at least one antiplatelet agent (aspirin 100 mg/day, clopidogrel 75 mg/day, or prasugrel 3.75 mg/day), with the choice of agent left to the discretion of the operator.
We calculated percent diameter stenosis before and after the DCB procedure by quantitative coronary angiography (QCA). The percent diameter stenosis was obtained as follows: The reference diameter was obtained by the site of minimal lumen diameter and derived by an iterative linear regression. Percent diameter stenosis was calculated by the minimal lesion diameter and the reference vessel diameter of the lesion of interest. 9) Clinical and angiographic follow-up: The primary endpoint was target lesion revascularization (TLR). The secondary endpoints were all revascularizations including target vessel revascularization (TVR) and non-target vessel revascularization, and MACE was defined as cardiac death, myocardial infarction (MI), or cerebral infarction. Revascularization required the presence of clinical or functional ischemia and > 75% diameter stenosis of one or more vessels. TLR was defined as the revascularization of the recurrent ISR by DCB, which had been performed previously for ISR at the time of study enrollment. TVR was defined as the revascularization of a vessel in which DCB was performed including the target lesion. The stenoses in coronary angiography (CAG) findings were evaluated by at least two operators performing CAG. If the evaluation of stenoses differed between the evaluators, evaluation by the intervention team, including more than two cardiologists certified by the Japanese Association of KIRIYAMA, ET AL Cardiovascular Intervention and Therapeutics, was undertaken. The decision to perform revascularization was also based on the consensus of more than two interventional cardiologists. MI was defined as myocardial necrosis due to myocardial ischemia that resulted in an increase in specific biomarkers such as troponin I or T. 10) Cerebral infarction was defined as the presence of neuropathological, neuroimaging and/or clinical evidence of permanent injury. 11) We compared the rates of revascularization and MACE between the HD patients and non-HD patients. Patient follow-ups lasted for up to 3 years. Statistical analysis: Variables with a normal distribution are expressed as the mean ± standard deviation (SD). The difference between the two groups for continuous variables was compared using the Mann-Whitney U test or Student's t-test. The incidence of all categorical variables was compared between the two groups using a chi-square test. Kaplan-Meier curves of survival free from TLR were compared between the HD and non-HD groups using a log-rank test. Given the differences in the characteristics of patients between the HD and non-HD groups, propensity score matching was used to identify HD and non-HD patients with similar baseline features. The propensity score was estimated using age, gender, hypertension, diabetes mellitus, dyslipidemia, family history of CAD, history of smoking, the number of the stents, calcification, recurrence of ISR, multivessel disease, and the SYNTAX score. Matching was performed using a 1:1 matching protocol without replacement and with a caliper width equal to 0.2 SD of the logit of the propensity score. All baseline and outcome variables were compared between the HD and non-HD groups in the propensity-matched cohort. The correlation of QCA between inter-observer variability was examined by using the intraclass correlation coefficient (ICC). Two evaluators examined QCA in a portion of the patients in the present study and calculated the ICC retrospectively. All statistical analyses were performed with JMP Pro 13.2.0. A P value < 0.05 was considered significant.
Results
Patient, lesion, and procedure characteristics: There were 39 patients (25%) in the HD group and 114 (75%) in the non-HD group. The overall patient characteristics of the HD and non-HD groups are shown in Table I . Although age was higher in the non-HD group than in the HD group, there were no significant differences in gender or BMI between the two groups. The prevalence of diabetes mellitus including insulin use was higher in the HD group than in the non-HD group, while the prevalence of dyslipidemia was higher in the non-HD group. Left ventricular ejection fraction was lower in the HD group than in the non-HD group. Regarding past illness, the prevalence of peripheral artery disease was significantly higher in the HD group than in the non-HD group, although the prevalence of other vascular diseases did not differ between the groups. In terms of medical therapy, statins were prescribed more frequently for non-HD patients than for HD patients, whereas there were no significant differences in the use of antiplatelet therapy and antihyperten-sive therapy in both groups.
The lesion and procedure characteristics in the HD and non-HD groups are also shown in Table I . More stents were implanted in the HD group than the non-HD group. The last implanted stents were DES in all HD patients, however, BMS were selected in some non-HD patients. The recurrence of ISR was more common in HD patients than in non-HD patients. The HD group had a significantly higher incidence of lesion calcification than the non-HD group, and the SYNTAX score was significantly higher in the HD group. There were no significant differences in the DCB length or diameter between the two groups. The percent diameter stenosis before the DCB procedure was higher in the HD group than non-HD group, whereas there was no significant difference in the percent diameter stenosis after DCB. The ICC of QCA between the two examiners was 0.953. The acute procedure success rate was similar for the HD and non-HD groups (100% versus 99.1%, P = 0.56).
After propensity score matching, there were 27 patients in the HD group and 27 in the non-HD group. The clinical and angiographic characteristics in these two groups are shown in Table II . There were almost no significant differences in the characteristics of the patients, lesions or procedures between the HD and non-HD groups in the propensity-matched cohort.
Clinical events: Table III shows the cardiovascular events in the two groups in the overall cohort, and Table IV shows the events in the propensity-matched cohort. TLR was significantly higher in the HD group than in the non-HD group in both the overall cohort and the propensitymatched cohort. The overall revascularization and TVR rates were also higher in the HD group than in the non-HD group in both cohorts. The revascularization rate of non-target vessels was similar for the HD and non-HD groups in both cohorts. Hard endpoints such as cardiac death and MI were more frequent in the HD group than in the non-HD group in both cohorts. As a result, there was a higher incidence of MACE in the HD group than in the non-HD group. The MACE and revascularization rates combined were significantly higher in the HD group than in the non-HD group in both cohorts.
Kaplan-Meier curves of survival free from TLR for the HD and non-HD groups are shown in the overall cohort in Figure 2A and in the propensity-matched cohort in Figure 2B . Survival free from TLR was significantly lower in the HD group than in the non-HD group in both cohorts.
Discussion
The major finding of the present study was that the rate of TLR in the chronic phase after DCB for ISR was higher in the HD group than in the non-HD group, despite similar acute success rates. The incidences of the secondary endpoints such as overall revascularization, TVR and MACE after DCB were also higher in the HD group than in the non-HD group. The unique aspect of this study is that it compared the outcomes of DCB for ISR between HD and non-HD patients both before and after propensity score matching. To the best of our knowledge, there is no THE EFFICACY OF DCB IN HD PATIENTS study that has compared the clinical outcomes of DCB to treat ISR for HD and non-HD patients. In this study, the percentage of HD patients in the entire cohort treated with DCB was higher than that in a previous study (25% versus 10%). 12) This is probably be-cause our institution has a greater population of HD patients than other institutions. The TLR rate after DCB in the non-HD group was 9.6% in our study, which is similar to the rate reported in a previous study. 12) In terms of procedure success, our result is acceptable compared with KIRIYAMA, ET AL Values are mean ± standard deviation (SD) where appropriate. HD indicates hemodialysis; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PAD, peripheral artery disease; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; QCA, quantitative coronary angiography; and DCB, drug-coated balloon. a previous study, even though more HD patients were included in our study. 13) Regarding the percent diameter stenosis from QCA data, there is no significant difference in that after the DCB procedure. Acute gains after DCB in HD patients were fully obtained. Therefore, we suggest that our PCI procedure was not the cause of the high ISR There are several studies that have compared the outcomes of PCI for HD and non-HD patients, because endstage renal disease is associated with a very high mortality rate. 14) Nonetheless, a few studies have shown that PCI for native vessel stenosis in HD patients had poorer outcomes than in non-HD patients. The probability of repeat revascularization after first-generation DES implantation to treat new lesions was reported to be as high as up to 19% in HD patients. 15) Ikari, et al. reported that the rate of target vessel failure and late lumen loss after secondgeneration DES implantation to treat new lesions was higher in HD patients. 16) In the present study, the outcomes of DCB to treat ISR were worse in HD patients than in non-HD patients. These findings are consistent with previous studies. In addition to the numerous complications in HD patients, HD itself can influence the outcome after DES implantation or DCB.
Unfortunately, the outcomes of DCB for ISR in HD patients were not favorable in the present study, contrary to the good short-term efficacy of DCB in HD patients from the perspective of the similar percent diameter stenosis after DCB and acute procedure success between HD and non-HD patients. The long-term efficacy of DCB may well depend on the area and amount of antiproliferative drug that can be infiltrated into the vessel wall. However, even DCB could not benefit HD patients because of the large extent of calcification in vessel walls due to vessel wall heterogeneity. Ito, et al. evaluated DCB to treat de novo coronary lesions and reported that clinical outcomes at 2 years in the calcified group were similar to those in the non-calcified group. 17) However, rotational atherectomy was performed at a high rate (> 80%) in that study, suggesting that DCB can prevent restenosis only if the lesion is modified aggressively so that an antiproliferative drug can work. In our study, only 10.3% of HD patients had rotational atherectomy, which might have led to a poor outcome. Adequate lesion preparation before drug application by DCB has been strongly recommended. 18) Moreover, DCB for ISR in HD patients had worse outcomes in the present study, however, other PCI procedures for HD patients also do not have good results. Therefore, further study should be conducted from other perspectives like cost-effectiveness. 19) Limitations: There are several limitations to this study. First, this was a retrospective study with a small population in a single institution. Second, the coronary intervention procedures were selected by the attending physician, and differences in individual practice (e.g., use of the radial artery for PCI) may have influenced the clinical out-come. Third, selection bias of the operators may be present. HD patients who have re-restenosis of the stent tend to require repeated PCI. Implantation of the new stent for the re-restenosis can evoke further narrowing of the vessel lumen, which can limit the next treatment for the repeated restenosis. Therefore, operators may select DCB for a palliative treatment until the recurrence of ISR in the future, and keep the vessel lumen as wide as possible.
Conclusion
The short-term efficacy of DCB in HD patients was proven from the viewpoint of rate of acute procedure success. On the other hand, recurrent ISR and MACE occurred more frequently in HD patients than in non-HD patients after DCB, which indicated poorer long-term efficacy of DCB in HD patients.
Disclosures
Conflicts of interest:
The authors have no conflicts of interest to disclose.
